

FORM PTO 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION	Attorney Docket No. 81190-1802	Serial No. 10/507,495
	Applicant Peter Zahradka	
	Filing Date 03/11/2003	Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	DATE	NAME	Class	Sub Class	Filing Date
	4,156,003	05/22/1979	METZ ET AL			
	4,240,191	02/10,1981	EDWARDS			
	4,976,970	12/11/1990	LANDY			
	5,593,971	01/14/1997	TSCHOLLAR ET AL			
	5,880,148	03/09/1999	Edgar et al			

FOREIGN PATENT DOCUMENTS

	Document Number	DATE	COUNTRY	Class	Sub Class	
	WO98/05331	12/02/1998	Ligand Pharmaceuticals Incorporated			
	WO01/27128	19/04/2001	Bristol-Myers Squibb Company			
	WO02/09682	07/02/2002	Sigma-Tau Industrie Farmaceutiche Riunite			
	WO02/34259	02/05/2002	Fournier Laboratories Ireland Limited			
	WO01/60807	23/08/2001	Merck & Co. Inc.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	Bernadette, P. Neve, Jean Charles Fruchart and Bart Staels; "Role of the Peroxisome Proliferator-Activated Receptors (PPAR) in Atherosclerosis" Biochemical Pharmacology Vo. 60 PP 1245-1250, 2000.
	Daniela Hornung et al "Nuclear Peroxisome Proliferator-Activated Receptors α and γ Have Opposing Effects on Monocyte Chemotaxis in Endometriosis" The Journal of Clinical Endocrinology & Metabolism Copyright 2001 by the Endocrine Society
	Takako Hamano et al "Peroxisome Proliferator-Activated Receptor α (PPAR α) Agonist, WY-14,643 Increased Transcription of Myosin Light Chain-2 In Cardiomyocytes: - The Journal of Toxicological Sciences, Vo. 26 No. 5, 275-284, 2001
	"Ligands for Peroxisome Proliferator-activated Receptors α and γ Inhibit Chemically Induced Colitis and Formation of Abberant Crypt Foci in Rats" Cancer Research 61,2424-2428 March 15, 2001

Examiner	Date Considered
----------	-----------------